Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response

  1. Paola Storti
  2. Valentina Marchica
  3. Rosanna Vescovini
  4. Valentina Franceschi
  5. Luca Russo
  6. Laura Notarfranchi
  7. Vincenzo Raimondi
  8. Denise Toscani
  9. Jessica Burroughs Garcia
  10. Federica Costa
  11. Benedetta Dalla Palma
  12. Nicolas Thomas Iannozzi
  13. Gabriella Sammarelli
  14. Gaetano Donofrio
  15. Nicola Giuliani

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1080/2162402x.2022.2120275
  2. ScreenIT

    SciScore for 10.1101/2022.02.25.22271501: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: In a subset of 16 patients with MM (MMD and MMR), blood samples were also collected after 14±2 days of a heterologous booster dose (BOOSTER) with mRNA-1273 by Moderna, received, in November 2021, at least six months (>180 days) after the complete vaccination (Fig.4A) Ethics statement: PB samples were obtained according to the criteria of the Declaration of Helsinki and following written informed consent.
    IRB: The study was approved by the Local Ethics Committee.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Detection of SARS-CoV-2-specific IgG antibodies: Heat inactivated sera samples were tested for SARS-CoV-2-specific IgG antibodies using a commercial quantitative two-step ELISA (COVID-SeroIndex, Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit, R&D Systems), according to the manufacturer’s recommendations.
    SARS-CoV-2-specific IgG
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    The neutralization assay was performed on 104 HEK/ACE2/TMPRRS2/Puro cells 18 testing heat inactivated sera samples at the dilution of 1:4–1:8–1:16–1:32–1:64–1:128–1:256–1:512 as described in Supplemental Methods.
    HEK/ACE2/TMPRRS2/Puro
    suggested: None
    Software and Algorithms
    SentencesResources
    Samples were acquired on a BD Bioscience FACSCelesta flow cytometer using the FACSDiva Software (version 8.02, BD Bioscience).
    FACSDiva
    suggested: (BD FACSDiva Software, RRID:SCR_001456)
    Data analysis, as well as all graphical representation of the data, were performed in GraphPad Prism v.8.0.1 software.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.02.25.22271501v1 on medRxiv